CD49 in Optimization The Cologenicity of Mesenchymal Stem Cell Culture Passage

• Conditions: Umbilical Cord of Normal Labor

• Registration Number: NCT05093725
• Lead Sponsor: Sohag University

Brief Summary

Human mesenchymal stem cells (MSCs) due to their regenerative and immunomodulatory properties are widely used for the treatment of bone and cartilage damage, cardiovascular, gastrointestinal, autoimmune, neurodegenerative diseases and cancer .It is shown that the use of MSCs in therapy is safe and can be effective .In 2006, the International Society for Cellular Therapy (ISCT) proposed the minimal criteria to define human MSCs. First, MSCs must be plastic-adherent when maintained in the standard culture conditions. Second MSCs must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR surface molecules.

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-10
• Study First Submitted: 2021-10-13
• Study First Submitted QC: 2021-10-13
• Last Update Submitted: 2021-10-13
• Study First Posted: 2021-10-26
• Last Update Posted: 2021-10-26
• Study Start: 2021-11
• Primary Completion: 2022-06
• Study Completion: 2022-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

normal babies delivered by normal labor

Exclusion Criteria

diseased or congenital anomalies

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evaluation the best passage of MSC culture by CD49 surface marker	7 months	evaluation the best passage of MSC culture by CD49 surface marker

Trial Locations

Locations (1)

Sohag University Hospital; 🇪🇬 Sohag, Egypt